A survey of patient preferences for a placebo orodispersible tablet

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 201-206

  Wade, Alan G ^a   Crawford, Gordon M ^a   Young, David ^b  

^a CPS Research   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Antidepressant; Anxiety; Depression; ODT; Swallowing difficulties

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; GENERAL PRACTICE; HEALTH SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RATING SCALE; SCORING SYSTEM; SWALLOWING; TABLET FORMULATION; TASTE DISORDER;

EID: 84885970046     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S28283     Document Type: Article

References (12)

1. Nilausen DØ, Zuiker R, van Gerven J. The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Clin Ther. 2011;33(10):1492-1502.
2. Hunter PC, Crameri J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry. 1997;63(5):579-583.
3. Navarro V. Improving medication compliance in patients with depression: Use of orodispersible tablets. Adv Ther. 2010;27(11):785-795.
4. Llorca P-M. Discussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depression. Ther Deliv. 2011;2(5):611-622.
5. Andersen O, Zweidorff OK, Hjelde T, Rødland EA. Problems when swallowing tablets. A questionnaire study from general practice. Tidsskr Nor Laegeforen. 1995;115(8):947-949. Norwegian.
6. Márquez-Contreras E, Gil V, López J, et al. Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care. Curr Med Res Opin. 2008;24(2):569-576.
7. Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J Exp Med. 2008;216(3):249-257.
8. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
9. Wade AG, Crawford GM, Bezlyak V. Wellbeing of patients prescribed long-term SSRIs by general practitioners in the UK [abstract]. Eur Neuropsychopharmacol. 2008;18 Suppl 4:S333.
10. Regan J, Sowman R, Walsh I. Prevalence of dysphagia in acute and community mental health settings. Dysphagia. 2006;21(2):95-101.
11. Roose SP. Compliance: the impact of adverse events and tolerability on the physician's treatment decisions. Eur Neuropsychopharmacol. 2003;13 Suppl 3:S85-S92.
12. Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol. 2006;26:75-78.